Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells

Experimental Cell Research

Volumn 316, Issue 20, 2010, Pages 3425-3434

  Law, Alice Y S ^a   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

EMT; HUVEC; MMP2; MMP9; ROS; Snail

Indexed keywords

BIOLOGICAL MARKER; HYPOCALCIN; HYPOCALCIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER CELL; CANCER INVASION; CELL MOTILITY; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOCYTOCHEMISTRY; METASTASIS; MORPHOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

GASTROPODA;

EID: 78149416513     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.06.026     Document Type: Article

References (56)

1. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
2. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-6465.
3. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
4. Hill R.P., Marie-Egyptienne D.T., Hedley D.W. Cancer stem cells, hypoxia and metastasis. Semin. Radiat. Oncol. 2009, 19:106-111.
5. Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2:41-53.
6. Kim Y., Lin Q., Glazer P.M., Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med. 2009, 9:425-434.
7. Anderson A.R., Weaver A.M., Cummings P.T., Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127:905-915.
8. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15:678-685.
9. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
10. Gort E.H., Groot A.J., van der W.E., van Diest P.J., Vooijs M.A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr. Mol. Med. 2008, 8:60-67.
11. Banerjee S., Gore M. The future of targeted therapies in ovarian cancer. Oncologist 2009, 14:706-716.
12. Roett M.A., Evans P. Ovarian cancer: an overview. Am. Fam. Physician 2009, 80:609-616.
13. Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol. Oncol. 2009, 113:143-148.
14. Tan D.S., Agarwal R., Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006, 7:925-934.
15. Krtolica A., Ludlow J.W. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res. 1996, 56:1168-1173.
16. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., Wang Y., Kristensen G.B., Helland A., Borresen-Dale A.L., Giaccia A., Longaker M.T., Hastie T., Yang G.P., van de Vijver M.J., Brown P.O. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006, 3:e47.
17. Chaudary N., Hill R.P. Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab. Invest. 2009, 89:587-596.
18. Lunt S.J., Chaudary N., Hill R.P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 2009, 26:19-34.
19. Chaudary N., Hill R.P. Hypoxia and metastasis. Clin. Cancer Res. 2007, 13:1947-1949.
20. Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., Botbyl J., Hammond R., Katsaros D., Sandaltzopoulos R., Liotta L.A., Gimotty P.A., Coukos G. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol. 2007, 25:852-861.
21. Chang A.C., Jellinek D.A., Reddel R.R. Mammalian stanniocalcins and cancer. Endocr. Relat. Cancer 2003, 10:359-373.
22. Esseghir S., Kennedy A., Seedhar P., Nerurkar A., Poulsom R., Reis-Filho J.S., Isacke C.M. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin. Cancer Res. 2007, 13:3164-3173.
23. Iwao K., Matoba R., Ueno N., Ando A., Miyoshi Y., Matsubara K., Noguchi S., Kato K. Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum. Mol. Genet. 2002, 11:199-206.
24. McBryan J., Howlin J., Kenny P.A., Shioda T., Martin F. ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 2007, 26:6406-6419.
25. Meyer H.A., Tolle A., Jung M., Fritzsche F.R., Haendler B., Kristiansen I., Gaspert A., Johannsen M., Jung K., Kristiansen G. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur. Urol. 2009, 55:669-678.
26. Leonard M.O., Cottell D.C., Godson C., Brady H.R., Taylor C.T. The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J. Biol. Chem. 2003, 278:40296-40304.
27. Law A.Y., Lai K.P., Ip C.K., Wong A.S., Wagner G.F., Wong C.K. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp. Cell Res. 2008, 314:1823-1830.
28. Law A.Y., Wong C.K. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp. Cell Res. 2010, 316:466-476.
29. Ito D., Walker J.R., Thompson C.S., Moroz I., Lin W., Veselits M.L., Hakim A.M., Fienberg A.A., Thinakaran G. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol. Cell. Biol. 2004, 24:9456-9469.
30. Tamura K., Furihata M., Chung S.Y., Uemura M., Yoshioka H., Iiyama T., Ashida S., Nasu Y., Fujioka T., Shuin T., Nakamura Y., Nakagawa H. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 2009, 100:914-919.
31. Ieta K., Tanaka F., Yokobori T., Kita Y., Haraguchi N., Mimori K., Kato H., Asao T., Inoue H., Kuwano H., Mori M. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int. J. Cancer 2009, 125:926-931.
32. Volland S., Kugler W., Schweigerer L., Wilting J., Becker J. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int. J. Cancer 2009, 125:2049-2057.
33. Yokobori T., Mimori K., Ishii H., Iwatsuki M., Tanaka F., Kamohara Y., Ieta K., Kita Y., Doki Y., Kuwano H., Mori M. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann. Surg. Oncol. 2010.
34. Bouras T., Southey M.C., Chang A.C., Reddel R.R., Willhite D., Glynne R., Henderson M.A., Armes J.E., Venter D.J. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 2002, 62:1289-1295.
35. Sahlgren C., Gustafsson M.V., Jin S., Poellinger L., Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl Acad. Sci. USA 2008, 105:6392-6397.
36. Nguyen A., Chang A.C., Reddel R.R. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene 2009, 28:1982-1992.
37. Sheikh-Hamad D. Mammalian stanniocalcin-1 activates mitochondrial anti-oxidant pathways: new paradigms for the regulation of macrophages and endothelium. Am. J. Physiol. Renal. Physiol. 2009.
38. Honda S., Kashiwagi M., Ookata K., Tojo A., Hirose S. Regulation by 1alpha, 25-dihydroxyvitamin D(3) of expression of stanniocalcin messages in the rat kidney and ovary. FEBS Lett. 1999, 459:119-122.
39. Ishibashi K., Miyamoto K., Taketani Y., Morita K., Takeda E., Sasaki S., Imai M. Molecular cloning of a second human stanniocalcin homologue. Biochem. Biophys. Res. Commun. 1998, 250:252-258.
40. Ishibashi K., Imai M. Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am. J. Physiol. Renal. Physiol. 2002, 282:F367-F375.
41. Wong C.K., Yeung H.Y., Mak N.K., DiMattia G.E., Chan D.K., Wagner G.F. Effects of dibutyryl cAMP on stanniocalcin and stanniocalcin-related protein mRNA expression in neuroblastoma cells. J. Endocrinol. 2002, 173:199-209.
42. Pani G., Giannoni E., Galeotti T., Chiarugi P. Redox-based escape mechanism from death: the cancer lesson. Antioxid. Redox Signal. 2009, 11:2791-2806.
43. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7:1875-1884.
44. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett. 2008, 266:53-59.
45. Wang Z., Li Y., Sarkar F.H. Signaling mechanism(s) of reactive oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem cells in tumor progression. Curr. Stem. Cell Res. Ther. 2009.
46. Wu W.S., Wu J.R., Hu C.T. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev. 2008, 27:303-314.
47. Wu W.S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006, 25:695-705.
48. Kumar B., Koul S., Khandrika L., Meacham R.B., Koul H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008, 68:1777-1785.
49. Joensuu K., Heikkila P., Andersson L.C. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 2008, 265:76-83.
50. Raulic S., Ramos-Valdes Y., DiMattia G.E. Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. J. Endocrinol. 2008, 197:517-529.
51. Keibel A., Singh V., Sharma M.C. Inflammation, microenvironment, and the immune system in cancer progression. Curr. Pharm. Des. 2009, 15:1949-1955.
52. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
53. Makrilia N., Lappa T., Xyla V., Nikolaidis I., Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur. J. Intern. Med. 2009, 20:663-671.
54. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe?. Cell Cycle 2009, 8:3291-3296.
55. Furuya M., Yonemitsu Y., Aoki I. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr. Pharm. Des. 2009, 15:1854-1867.
56. Tang H.S., Feng Y.J., Yao L.Q. Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:605-610.